# EDGAR Filing Document

**Accession Number:** 0000875320
**File Stem:** 0000875320-25-000242
**Filing Date:** 2025-12
**Character Count:** 8967
**Document Hash:** d69c890891db84f6cbc3edbe38014256
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000875320-25-000242.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0000875320-25-000242

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251203

**FILED AS OF DATE**: 20251205

**DATE AS OF CHANGE**: 20251205

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LEIDEN JEFFREY M
- **CENTRAL INDEX KEY:** 0001242825

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19319
- **FILM NUMBER:** 251553075

**MAIL ADDRESS:**
- **STREET 1:** 127 SOUTH BEACH RD
- **CITY:** HOBE SOUND
- **STATE:** FL
- **ZIP:** 33455
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VERTEX PHARMACEUTICALS INC / MA
- **CENTRAL INDEX KEY:** 0000875320
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043039129
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6173416393

**MAIL ADDRESS:**
- **STREET 1:** 50 NORTHERN AVENUE
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LEIDEN JEFFREY M<br><sub>(Last) (First) (Middle)</sub><br>C/O VERTEX PHARMACEUTICALS INCORPORATED<br>50 NORTHERN AVENUE<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Executive Chairman_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VERTEX PHARMACEUTICALS INC / MA [ VRTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-03 |  | M |  | 63781 | A | $86.52 | 87807 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 4469 | D | 440.40<sup>(2)(3)</sup> | 83338 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 1320 | D | 441.26<sup>(2)(4)</sup> | 82018 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 2469 | D | 443.21<sup>(2)(5)</sup> | 79549 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 4352 | D | 444.36<sup>(2)(6)</sup> | 75197 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 7899 | D | 445.56<sup>(2)(7)</sup> | 67298 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 1152 | D | 447.05<sup>(2)(8)</sup> | 66146 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 2320 | D | 448.78<sup>(2)(9)</sup> | 63826 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 5880 | D | 449.84<sup>(2)(10)</sup> | 57946 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 5809 | D | 451.20<sup>(2)(11)</sup> | 52137 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 15681 | D | 452.20<sup>(2)(12)</sup> | 36456 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 10360 | D | 453.34<sup>(2)(13)</sup> | 26096 | D |  |
| Common Stock | 2025-12-03 |  | S<sup>(1)</sup> |  | 2070 | D | 455.22<sup>(2)(14)</sup> | 24026 | D |  |
| Common Stock | 2025-12-04 |  | M |  | 1 | A | $91.05 | 24027 | D |  |
| Common Stock |  |  |  |  |  |  |  | 440 | I | 401(k) |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $86.52 | 2025-12-03 |  | M |  |  | 63781 | <sup>(15)</sup> | 2027-02-02 | Common Stock | 63781 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $91.05 | 2025-12-04 |  | M |  |  | 1 | <sup>(15)</sup> | 2026-02-01 | Common Stock | 1 | $0 | 0 | D |  |

---

### Footnotes:

(1) Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025.

(2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(3) Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00).

(4) Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00).

(5) Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93).

(6) Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94).

(7) Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82).

(8) Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23).

(9) Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12).

(10) Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18).

(11) Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70).

(12) Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69).

(13) Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70).

(14) Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66).

(15) Fully vested.

**Signature:** /s/ Christiana Stevenson, Attorney-in-Fact  
**Date:** 2025-12-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**